Targeted drug cocktail shows promise for rare prostate cancer mutation
NCT ID NCT05689021
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tests a two-drug combination (niraparib/abiraterone plus prednisone) in men with a specific genetic change (SPOP mutation) in their advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the drugs can shrink tumors or slow the cancer. Only 8 participants were enrolled, so results are very early and not conclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.